Discovery of therapeutic antibodies targeting breast cancer metastasis using Enabled G-Protein-Coupled Receptors
使用启用的 G 蛋白偶联受体发现针对乳腺癌转移的治疗抗体
基本信息
- 批准号:9256138
- 负责人:
- 金额:$ 30万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-09-19 至 2018-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAffinityAgonistAnimalsAntibodiesAntigensAutomobile DrivingBacteriophagesBehaviorBindingBiological AssayBiological Response Modifier TherapyBiotechnologyBone MarrowBreast Cancer CellBreast cancer metastasisCancer PatientCell LineCell ProliferationClinicalClinical ResearchCombined Modality TherapyComplementComplexCytotoxic T-Lymphocyte-Associated Protein 4DevelopmentDinoprostoneDirected Molecular EvolutionDisseminated Malignant NeoplasmDiversity LibraryDrug TargetingEctopic ExpressionEnvironmentEnzyme-Linked Immunosorbent AssayFlow CytometryFundingG-Protein-Coupled ReceptorsGene LibraryGenerationsGrowthHeterogeneityHomingHomology ModelingImmuneImmune responseImmunizationImmunotherapyIn VitroJapanLeadLeukocyte TraffickingLibrariesLiverLungMalignant NeoplasmsMammalian CellMapsMembraneMembrane ProteinsMetastatic breast cancerMetastatic toMethodsModalityMolecularMolecular ConformationMutagenesisMutationNeoplasm MetastasisOrganOutcomePDCD1LG1 genePatternPhage DisplayPharmacologyPhasePrimary NeoplasmProcessPropertyProstaglandin ReceptorProstaglandinsProteinsSignal TransductionSiteSmall Business Innovation Research GrantSpecificitySystemTechnologyTestingTherapeuticTherapeutic antibodiesToxic effectTumor Cell MigrationVariantWFDC2 geneabstractingantibody librariesbasecancer cellcancer therapychemokinechemokine receptorgenetic variantimprovedin vivo Modelinhibitor/antagonistinnovationlymph nodesmalignant breast neoplasmmigrationneoplastic cellnew technologynovel therapeuticspersonalized medicineprecision medicinepressurereceptorsmall moleculetargeted treatmenttherapy designthermostabilitytooltumor
项目摘要
Project Summary/Abstract
Abilita Bio (AB), an innovation driven biotechnology company, requests SBIR Phase I funding for the
discovery of novel therapeutic antibodies targeting G protein-coupled receptors (GPCRs) for the treatment
of metastatic breast cancer.
In cancer therapy each treatment modality has its own limitations. Clinical studies clearly indicate that
immunotherapy with checkpoint inhibitors (PD-1/PD-L1, CTLA-4 etc.) can achieve a persistent immune
response with improved clinical outcomes. However, this approach is especially effective when administered
in combination therapy with targeted therapy aiming at essential components of tumor spreading, homing
and growth especially in metastatic cancer. Metastasis is the major factor limiting survival in cancer patients.
Therefore, interfering with the molecular mechanisms controlling the metastatic behavior of tumor cells is
essential for successfully treating cancer.
Experimental and clinical evidence supports the notion that one of the most important mechanisms
operating in metastasis involves homeostatic chemokines and their receptors. Breast cancer is
characterized by a distinct metastatic pattern involving the regional lymph nodes, bone marrow, lung and
liver. Tumor cell migration from the primary tumor site to the metastatic homing sites shares many similarities
with leukocyte trafficking, which is critically regulated by chemokine-binding GPCRs. Interestingly, several
studies have established that prostaglandin E2 (PGE2) secretion by breast cancer cells can upregulate
CCR7 expression via activation of prostaglandin-binding GPCRs, EP2 and EP4. This proposal focuses on
targeting key GPCRs critically involved in tumor cells metastatic migration and organ-specific invasion using
therapeutic antibodies.
The use of therapeutic antibodies to target GPCRs has a tremendous potential for the treatment of cancer
because of their high affinity, exquisite specificity and low toxicity relative to small molecules. However,
GPCRs therapeutic antibody discovery is extremely challenging because of their inherent low stability, low
expression and conformational heterogeneity outside their natural membrane environment. In fact, only 1
GPCR-targeting antibody has been approved to date, and only in Japan. In order to overcome the afore
mentioned barriers, Abilita Bio offers an innovative solution through the generation of Enabled Membrane
Proteins (EMPs™), representing structurally and functionally enhanced versions of natural receptors with
significant improved expression and thermostability. The availability of highly expressing, stable and
functionally folded EMPs will enable the isolation of novel therapeutic antibodies using in vitro antibody
display methods.
Funds are requested to (a) generate mutational gene libraries for proposed targets and select for enhanced
variants using our directed evolution system; (b) characterize variants for expression, function and
enhanced stability in mammalian cells; (c) develop biopanning assay tools using evolved EMPs as antigens
and screen phage display antibody libraries for the isolation of preliminary antibody leads to be optimized
and developed in Phase II.
项目概要/摘要
Abilita Bio (AB) 是一家创新驱动的生物技术公司,请求 SBIR 第一阶段资金用于
发现针对 G 蛋白偶联受体 (GPCR) 的新型治疗抗体用于治疗
转移性乳腺癌。
在癌症治疗中,每种治疗方式都有其自身的局限性。临床研究清楚地表明
检查点抑制剂(PD-1/PD-L1、CTLA-4等)免疫治疗可实现持续免疫
反应并改善临床结果。然而,这种方法在施用时特别有效
与靶向治疗联合治疗,针对肿瘤扩散、归巢的重要组成部分
和生长,尤其是在转移性癌症中。转移是限制癌症患者生存的主要因素。
因此,干扰控制肿瘤细胞转移行为的分子机制是
对于成功治疗癌症至关重要。
实验和临床证据支持这样的观点:最重要的机制之一
转移中的作用涉及稳态趋化因子及其受体。乳腺癌是
其特点是具有明显的转移模式,涉及区域淋巴结、骨髓、肺和
肝。肿瘤细胞从原发肿瘤部位迁移到转移归巢部位有许多相似之处
白细胞运输受到趋化因子结合 GPCR 的严格调节。有趣的是,几个
研究证实乳腺癌细胞的前列腺素 E2 (PGE2) 分泌可以上调
CCR7 通过激活前列腺素结合 GPCR、EP2 和 EP4 表达。该提案的重点是
靶向与肿瘤细胞转移迁移和器官特异性侵袭密切相关的关键 GPCR
治疗性抗体。
使用靶向 GPCR 的治疗性抗体在治疗癌症方面具有巨大潜力
因为它们相对于小分子具有高亲和力、精细的特异性和低毒性。然而,
GPCR 治疗性抗体的发现极具挑战性,因为其固有的低稳定性、低
天然膜环境之外的表达和构象异质性。事实上,只有1
GPCR 靶向抗体迄今为止已获得批准,且仅在日本获得批准。为了克服上述问题
提到的障碍,Abilita Bio 通过生成启用膜提供了创新的解决方案
蛋白质 (EMPs™),代表天然受体的结构和功能增强版本
显着改善表达和热稳定性。具有高表达、稳定和
功能性折叠的 EMP 将能够使用体外抗体分离新型治疗抗体
显示方法。
需要资金(a)为拟议的目标生成突变基因库并选择增强的
使用我们的定向进化系统的变体; (b) 表征表达、功能和的变体
增强哺乳动物细胞的稳定性; (c) 使用进化的电磁脉冲作为抗原开发生物淘选测定工具
并筛选噬菌体展示抗体库,以优化初步抗体引线的分离
并在二期开发。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mauro Mileni其他文献
Mauro Mileni的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mauro Mileni', 18)}}的其他基金
Novel Anti-CCR8 VHH for the Treatment of NSCLC
用于治疗 NSCLC 的新型抗 CCR8 VHH
- 批准号:
10760140 - 财政年份:2023
- 资助金额:
$ 30万 - 项目类别:
Discovery of Novel Blood-Brain Barrier Targeting Antibodies for the Treatment of Alzheimer's Disease
发现用于治疗阿尔茨海默病的新型血脑屏障靶向抗体
- 批准号:
10254514 - 财政年份:2021
- 资助金额:
$ 30万 - 项目类别:
Discovery of therapeutic nanobodies targeting the G protein-coupled receptors in the brain for the treatment of Alzheimer Disease
发现针对大脑中 G 蛋白偶联受体的治疗性纳米抗体可用于治疗阿尔茨海默病
- 批准号:
9910106 - 财政年份:2019
- 资助金额:
$ 30万 - 项目类别:
相似海外基金
Discovery of a High Affinity, Selective and β-arrestin Biased 5-HT7R Agonist
发现高亲和力、选择性和β-抑制蛋白偏向的 5-HT7R 激动剂
- 批准号:
10412227 - 财政年份:2022
- 资助金额:
$ 30万 - 项目类别:
Discovery of a High Affinity, Selective and β-arrestin Biased 5-HT7R Agonist
发现高亲和力、选择性和β-抑制蛋白偏向的 5-HT7R 激动剂
- 批准号:
10610473 - 财政年份:2022
- 资助金额:
$ 30万 - 项目类别:
Supplement to Discovery of a high affinity, selective and beta-arrestinbiased 5-HT7R Agonist Grant
对高亲和力、选择性和 β 抑制偏向 5-HT7R 激动剂发现的补充补助金
- 批准号:
10799162 - 财政年份:2022
- 资助金额:
$ 30万 - 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
- 批准号:
6639179 - 财政年份:2001
- 资助金额:
$ 30万 - 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
- 批准号:
6724797 - 财政年份:2001
- 资助金额:
$ 30万 - 项目类别:
General Anesthetics and nAcCHOR Agonist Affinity
全身麻醉药和 nAcCHOR 激动剂亲和力
- 批准号:
6636512 - 财政年份:2001
- 资助金额:
$ 30万 - 项目类别:
General Anesthetics and nAcCHOR Agonist Affinity
全身麻醉药和 nAcCHOR 激动剂亲和力
- 批准号:
6326889 - 财政年份:2001
- 资助金额:
$ 30万 - 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
- 批准号:
6266928 - 财政年份:2001
- 资助金额:
$ 30万 - 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
- 批准号:
6539099 - 财政年份:2001
- 资助金额:
$ 30万 - 项目类别:
General Anesthetics and nAcCHOR Agonist Affinity
全身麻醉药和 nAcCHOR 激动剂亲和力
- 批准号:
6520329 - 财政年份:2001
- 资助金额:
$ 30万 - 项目类别:














{{item.name}}会员




